Tjokorda Gde Dalem Pemayun

Tjokorda Gde Dalem Pemayun

Auto-generated profile, based on publicly available information

Tjokorda Gde Dalem Pemayun

Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2023 in The Indonesian Biomedical Journal
Verified
Journal Article
Open access
PDF file
RARia Ambarwati
Ria Ambarwati
DSDamai Santosa
Damai Santosa
EPEko Adhi Pangarsa
Eko Adhi Pangarsa
BSBudi Setiawan
Budi Setiawan
MTMika Lumban Tobing
Mika Lumban Tobing
CSCatharina Suharti
Catharina Suharti
BACKGROUND: Metabolic syndrome (MetS), which is characterized by insulin resistance, adipocyte accumulation, and obesity, has been linked to malignancy development. Both leptin, an adipose tissue-produced cytokine-like hormone, and adiponectin, a hormone secreted by adipose tissue, play roles in the progression of MetS. However, the presence of leptin and adiponectin is also assumed to be associated with cancer proliferation. Therefore, it is necessary to investigate the profile of leptin and adiponectin levels in MetS patients with malignancy and non-malignancy.METHODS: This was a cross-sectional study involving 80 MetS subjects with and without malignancy. Leptin and adiponectin levels of subjects were analyzed by using the enzyme-linked immunosorbent assay (ELISA) method. Mann-Whitney tests were used to compare leptin and adiponectin levels between groups.RESULTS: Leptin levels were significantly higher in MetS patients with malignancy (32.99±22.47 ng/mL) than those without malignancy (6.17±7.46 ng/mL). Conversely, adiponectin levels were lower in the malignancy group (10.11±7.66 µg/mL) compared to the non-malignancy group (13.44±8.29 µg/mL), with both differences being statistically significant (p<0.001 for leptin, p=0.023 for adiponectin).CONCLUSION: Leptin levels were found to be higher while adiponectin levels were found to be lower in MetS patients with malignancy compared to those without malignancy. Therefore, it is suggested that leptin and adiponectin levels might be used as malignancy markers in MetS patients.KEYWORDS: adiponectin, leptin, metabolic syndrome, malignancy

1 January 2024 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
PDF file
WWWismandari Wisnu
Wismandari Wisnu
IAIdrus Alwi
Idrus Alwi
NNNafrialdi Nafrialdi
Nafrialdi Nafrialdi
TPTjokorda Gde Dalem Pemayun
Tjokorda Gde Dalem Pemayun
NPNico Iswanto Pantoro
Nico Iswanto Pantoro
ISImam Subekti
Imam Subekti
Wisnu W, et al. J Lipid Atheroscler. 2024 Sep;13(3):358-370. https://doi.org/10.12997/jla.2024.13.3.358

19 August 2024 in Medicina Moderna - Modern Medicine
Verified
Journal Article
Closed access
FNFarah Hendara Ningrum
Farah Hendara Ningrum
IRIgnatius Riwanto
Ignatius Riwanto
HSHermina Sukmaningtyas
Hermina Sukmaningtyas
KAKusworo Adi
Kusworo Adi
TPTjokorda Gde Dalem Pemayun
Tjokorda Gde Dalem Pemayun
MHMeita Hendrianingtyas
Meita Hendrianingtyas
Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is common liver disease often found and occurs in community. Prevalence of liver disease (NAFLD) has risen rapidly along with an increase obesity incidence in women. Inflammation condition in obese condition causing an increase in IL-6, Platelets Count (PLTC), and Aldosterone level increased risk of developing NAFLD. Aim: To analyze differences IL-6, PLTC, and Aldosterone level between Obese and Non-Obese Women. Methods: This study was an observational cross-sectional analytical study that conduct in NovemberJanuari 2021 at Diponegoro National Hospital (RSND) Semarang. Inclusion criteria for respondent in this study were being middle-aged women (30-49 years), healthy, and willing to take part in this study. Total respondent in this study was 60 people then divided into two groups that is Obese and Non-Obese Group. The degree of fatty liver was examined using the ultrasound method. Platelete count (PLTC) were measured by Indico Blood Analyzer. Meanwhile IL-6 and Aldosterone level analyzed by the enzyme-linked immunosorbent assay (ELISA) method. Fatty liver was diagnosed by abdominal ultrasound. Data were analyze using SPSS 18.0 that including normality, different test, and regression test. Result: Incidence of fatty liver in the obese group was significantly different from the non-obese group (p 0.005). No significant different average aldosterone serum, and AST between two group. Platelete Count (PLTC), IL-6 between two groups was showed significantly difference between two group. Conclusion: Obesity will trigger an increase in IL-6 and PLT which can increase the risk of fatty liver.